-
-
Final analysis of the Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial. J. Urol. (IF 7.6) Pub Date : 2022-08-10 Paul Doan, Matthijs J Scheltema, Amer Amin, Ron Shnier, Bart Geboers, William Gondoputro, Daniel Moses, Pim J van Leeuwen, Anne Maree Haynes, Jayne Matthews, Phillip Brenner, Gordon O'Neill, Carlo Yuen, Warick Delprado, Phillip Stricker, James Thompson
This study aimed to assess the medium-term oncologic outcomes of an active surveillance protocol, replacing confirmatory biopsy with serial multiparametric MRI (mpMRI).
-
AUA Diversity & Inclusion Task Force: Blueprint and Process for Justice, Equity, Diversity and Inclusion. J. Urol. (IF 7.6) Pub Date : 2022-08-09 Simone Thavaseelan,Arthur L Burnett,Sam Chang,Benjamin Davies,Geolani Dy,Kirsten Greene,Tomas L Griebling,Yahir Santiago-Lastra,Linda L McIntire,Brian McNeil,Efe Chantal Ghanney Simons,Vijaya Vemulakonda,Hadley Wood,Tracy Downs
-
Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J. Urol. (IF 7.6) Pub Date : 2022-08-09 Jennifer T Anger, Brooke R Bixler, Rebecca S Holmes, Una J Lee, Yahir Santiago-Lastra, Shelley S Selph
In 2019 the American Urological Association (AUA) released the evidence-based guideline "Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline." Information supporting the guideline came from a 2019 systematic evidence review prepared for the AUA by the Pacific Northwest Evidence-based Practice Center (EPC). The AUA used evidence found for 11 Key Questions (Appendix C) in
-
Tension-Free Vaginal Tape and Polyacrylamide Hydrogel Injection for Primary Stress Urinary Incontinence: 3-Year Followup from a Randomized Clinical Trial. J. Urol. (IF 7.6) Pub Date : 2022-08-05 Anna-Maija Itkonen Freitas, Camilla Isaksson, Päivi Rahkola-Soisalo, Sari Tulokas, Maarit Mentula, Tomi S Mikkola
We sought to determine whether polyacrylamide hydrogel (PAHG) is noninferior to tension-free vaginal tape (TVT) in the treatment of women with primary stress urinary incontinence (SUI).
-
Diagnostic Code-Based Screening for Identifying Children with Primary Hyperoxaluria. J. Urol. (IF 7.6) Pub Date : 2022-08-05 Gregory Tasian, Kimberley Dickinson, John Karafilidis, Nicole Marchesani, Nuno Antunes, Hanieh Razzaghi, Levon Utidjian, Karyn Yonekawa, Doug Coplen, Samina Muneeruddin, Bob DeFoor, Kyle O Rove, Christopher Forrest, Christina Ching
We evaluated the utility of diagnostic codes to screen for patients with primary hyperoxaluria (PH) and evaluate their positive predictive value (PPV) in identifying children with this rare condition in PEDSnet, a clinical research network of pediatric health systems that shares electronic health records data.
-
Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer. J. Urol. (IF 7.6) Pub Date : 2022-08-05 Sophia M Abusamra, Marissa A Solorzano, Mallory Luke, Jake Quarles, Michelle F Jacobs, Sanjay Das, Amy Kasputis, Linda A Okoth, Milan Patel, Mariana Seymore, Megan E V Caram, Rodney L Dunn, Sofia D Merajver, Elena M Stoffel, Zachery R Reichert, Todd M Morgan
Indications for germline testing in prostate cancer patients have expanded substantially over the past decade. With a near-universal shortage of genetic counselors and increasing demand, increased access to genetic counseling is crucial. We sought to prospectively implement and assess a clinician-led approach to genetic counseling and testing.
-
Alcohol Intoxication is Associated with Bladder Injury and Bladder Surgical Repair in Patients Sustaining Motor Vehicle Collisions. J. Urol. (IF 7.6) Pub Date : 2022-08-02 Jason L Lui, Nizar Hakam, Nathan M Shaw, Joseph Cuschieri, Behzad Abbasi, Benjamin N Breyer
Alcohol intoxication is a known risk factor for Motor Vehicle Collisions (MVCs). We hypothesize ethanol intoxication increases the risk of bladder injury and surgical repair, especially at higher Blood Alcohol Content (BAC) levels.
-
Evaluating Tools for Characterizing Anterior Urethral Stricture Disease: A Comparison of the LSE System and the U-Score. J. Urol. (IF 7.6) Pub Date : 2022-08-01 Jane T Kurtzman, Rashed Kosber, Preston Kerr, Steven B Brandes
We evaluated if scores generated by the LSE Classification System and the U-Score (US) system are associated with intraoperative surgical complexity and stricture recurrence risk.
-
Addressing the Relationship Between Testosterone Levels and Urethral Stricture: A Case-Control Study. J. Urol. (IF 7.6) Pub Date : 2022-08-01 Ignacio Puche-Sanz, Almudena Sabio-Bonilla, Pedro Vila-Braña P, Juan Manuel Guardia-Baena, Mercedes Nogueras-Ocaña, Francisco Javier Contreras-Matos, Laura Entrena-Ureña, Ana Jimenez-Domínguez, Alba Tamayo-Gomez, Javier Vicente-Prados, Pablo Lardelli-Claret
Hypoandrogenism (HA) may have an association with urethral stricture (US). This study aimed to identify and quantify the association between testosterone levels and US.
-
Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer. J. Urol. (IF 7.6) Pub Date : 2022-07-28 Aaron Brant, Patrick Lewicki, Xian Wu, Christina Sze, Jeffrey P Johnson, Spyridon P Basourakos, Camilo Arenas-Gallo, Daniel Shoag, Christopher E Barbieri, Nicholas G Zaorsky, Jonathan E Shoag
Left-digit bias is a phenomenon in which the leftmost digit of a number disproportionately influences decision-making. We measured the effect of left-digit age bias on treatment recommendations for localized prostate cancer.
-
Healthcare Economic Burden of Treatment and Rehabilitation for Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. J. Urol. (IF 7.6) Pub Date : 2022-07-28 Aidin Abedi, Aref S Sayegh, Nhi T Ha, Anibal La Riva, Laura C Perez, Priya Kohli, Armita Abedi, Rita P Jen, David A Ginsberg, Evgeniy Kreydin
The clinical, social, and economic impacts of neurogenic lower urinary tract dysfunction (NLUTD) on individuals and healthcare systems are thought to be immense, yet the true costs of care are unknown. The aims of this study are to illuminate the global costs related to the current state of care for NLUTD.
-
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer. J. Urol. (IF 7.6) Pub Date : 2022-07-27 Ian M McElree, Ryan L Steinberg, Alex C Martin, Jordan Richards, Sarah L Mott, Paul T Gellhaus, Kenneth G Nepple, Michael A O'Donnell, Vignesh T Packiam
Bacillus Calmette-Guérin (BCG) is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive bladder cancer (NMIBC). In response to the BCG shortage, gemcitabine plus docetaxel (Gem/Doce) has been utilized at our institution in the BCG-naïve setting. We report the outcomes of patients with high-risk BCG-naïve NMIBC treated
-
Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial. J. Urol. (IF 7.6) Pub Date : 2022-07-18 Joseph D Shirk, Robert Reiter, Eric M Wallen, Ray Pak, Thomas Ahlering, Ketan K Badani, James R Porter
Planning complex operations such as robotic-assisted radical prostatectomy requires surgeons to review 2-dimensional magnetic resonance imaging (MRI) cross-sectional images to understand 3-dimensional (3D), patient-specific anatomy. We sought to determine surgical outcomes for robotic-assisted radical prostatectomy when surgeons reviewed 3D, virtual reality (VR) models for operative planning.
-
-
Con: Does COVID Impact Men's Health? J. Urol. (IF 7.6) Pub Date : 2022-07-15 Darshan P Patel,Sunni L Mumford,Alexander W Pastuszak,James M Hotaling
-
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. J. Urol. (IF 7.6) Pub Date : 2022-07-05 James A Eastham,Stephen A Boorjian,Erin Kirkby
-
Pro: Does COVID Affect Male Reproductive Health? J. Urol. (IF 7.6) Pub Date : 2022-07-05 Roei Golan,Akhil Muthigi,Ranjith Ramasamy
-
Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence. J. Urol. (IF 7.6) Pub Date : 2022-07-05 Christopher J Chermansky, Holly E Richter, Karny Jacoby, Wilson Titanji, Brenda Jenkins, Till Geib, Benjamin M Brucker
Intradetrusor injections of onabotulinumtoxinA are efficacious for the treatment of overactive bladder with urgency urinary incontinence in adults refractory to, or intolerant of, anticholinergics. Delivery of onabotulinumtoxinA via instillation would reduce the need for intradetrusor injections. The objective of this trial was to assess the efficacy and safety of intravesical instillation of an o
-
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment OF NON-MUSCLE Invasive Bladder Cancer. J. Urol. (IF 7.6) Pub Date : 2022-07-05 Ian M McElree, Vignesh T Packiam, Ryan L Steinberg, Sarah L Mott, Paul T Gellhaus, Kenneth G Nepple, Michael A O'Donnell
Intravesical gemcitabine-docetaxel (Gem/Doce) has emerged as an efficacious and well-tolerated salvage therapy for NMIBC. However, further rescue therapies are needed for subsequent recurrences or intolerance, particularly when cystectomy is refused or precluded. Valrubicin is an FDA-approved agent for BCG unresponsive disease, yet as monotherapy has demonstrated poor efficacy. We report our experience
-
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. J. Urol. (IF 7.6) Pub Date : 2022-07-05 Christopher P Filson, Kehao Zhu, Yijian Huang, Yingye Zheng, Lisa F Newcomb, Sierra Williams, James D Brooks, Peter R Carroll, Atreya Dash, William J Ellis, Martin E Gleave, Michael Liss, Frances Martin, Jesse K McKenney, Todd M Morgan, Andrew A Wagner, Lori J Sokoll, Martin G Sanda, Daniel W Chan, Daniel W Lin
We assessed whether Prostate Health Index (phi) results improve prediction of grade reclassification for men on active surveillance.
-
Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. J. Urol. (IF 7.6) Pub Date : 2022-07-05 Elio Mazzone, Giorgio Gandaglia, Armando Stabile, Carlo Andrea Bravi, Francesco Barletta, Simone Scuderi, Giuseppe Ottone Cirulli, Nicola Fossati, Vito Cucchiara, Daniele Raggi, Andrea Necchi, Francesco Montorsi, Alberto Briganti
Recent studies reported a potential benefit associated with adjuvant radiotherapy (aRT) for patients with adverse pathology features of prostate cancer. We hypothesized that not all the patients with adverse features may benefit from aRT and, therefore, observation +/- early salvage radiotherapy (eSRT) may still be considered in a subgroup of these patients.
-
The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy. J. Urol. (IF 7.6) Pub Date : 2022-07-05 Thilo Westhofen, Alexander Buchner, Veeru Kasivisvanathan, Simon Lennartz, Boris Schlenker, Armin Becker, Christian G Stief, Alexander Kretschmer
AbstractObjective:Several studies have shown baseline health-related quality of life (HRQOL) to be a valuable prognostic indicator of survival outcomes for various cancer entities in the metastatic setting. To date, there is no evidence regarding the prognostic value of baseline HRQOL for patients undergoing radical prostatectomy (RP) due to localized prostate cancer (PC).
-
Prostate-specific antigen (PSA) and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial. J. Urol. (IF 7.6) Pub Date : 2022-06-30 K Stinesen Kollberg, E Holmberg, A Josefsson, J Hugosson, R Arnsrud Godtman
Even when a screening study has demonstrated a mortality reduction, the degree of pre-testing and contamination is of importance as it can dilute the "true" effect of screening. Our object was to describe the level of pre-testing and contamination in the Göteborg-1 prostate cancer (PC) screening trial.
-
All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J. Urol. (IF 7.6) Pub Date : 2022-06-30 Kelly K Bree, Patrick J Hensley, Niyati Lobo, Nathan A Brooks, Graciela M Nogueras-Gonzalez, Charles C Guo, Neema Navai, H Barton Grossman, Colin P Dinney, Ashish M Kamat
There is variation amongst guidelines with respect to risk stratification of Ta tumors, specifically high-grade (HG) Ta tumors. We sought to investigate the response of all Ta tumors to bacillus Calmette-Guérin (BCG) and compare response rates based on European Association of Urology (EAU) classification as intermediate- (IR) or high-risk (HR).
-
The Lived Experience of Patients with Adult Acquired Buried Penis. J. Urol. (IF 7.6) Pub Date : 2022-06-29 Gregory M Amend, Jordan T Holler, Michael J Sadighian, Natalie Rios, Nizar Hakam, Behnam Nabavizadeh, Anthony Enriquez, Nathan Shaw, Alex J Vanni, Lee Zhao, Bradley A Erickson, Jill C Buckley, Benjamin N Breyer
We describe the lived experience of adults with acquired buried penis (AABP) through thematic analysis of patient interviews. We examine the challenges that patients face and the impacts of surgery.
-
A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes. J. Urol. (IF 7.6) Pub Date : 2022-06-28 Harshit Garg, Sarah P Psutka, Abraham Ari Hakimi, Hyung L Kim, Ahmed M Mansour, Deepak Pruthi, Michael A Liss, Hanzhang Wang, Christine S Gaspard, Chethan Ramamurthy, Robert S Svatek, Dharam Kaushik
Open radical nephrectomy with inferior vena cava thrombectomy (O-CT) is standard management for renal cell carcinoma with inferior vena caval thrombus. First reported a decade ago, robotic radical nephrectomy with caval tumor thrombectomy (R-CT) is a minimally invasive option for this disease. We aimed to perform a systematic review to assess the safety and feasibility of R-CT in terms of perioperative
-
Trends in Launch Prices and Price Increases for New Medicines for Urological Cancers. J. Urol. (IF 7.6) Pub Date : 2022-06-27 Thomas J Hwang,Symone Isaac-Wilkins,Quoc-Dien Trinh
-
Complications after Hypospadias Repair: Are We Adequately Counseling Families? J. Urol. (IF 7.6) Pub Date : 2022-06-24 James T Rague,Earl Y Cheng
-
Urology Residency Match: Trends and Costs. J. Urol. (IF 7.6) Pub Date : 2022-06-24 Zoe Guckien,Nikhi P Singh,Carter J Boyd,Soroush Rais-Bahrami
-
When Is Using a Prediction Model Better Than No Model to Inform Clinical Decision Making? J. Urol. (IF 7.6) Pub Date : 2022-06-24 Melissa Assel,Toby C Chai
-
Adoption of Single-Use Clean Intermittent Catheterization Policies Do Not Appear to Effect Genitourinary Outcomes in a Large Spinal Cord Injury Cohort. J. Urol. (IF 7.6) Pub Date : 2022-06-24 Christopher S Elliott, Kai Dallas, Kazuko Shem, James Crew
In April 2008, Medicare amended their policy for clean intermittent catheter (CIC), increasing coverage from 4 re-used catheters per month to up to 200 single-use catheters. The primary reason for the policy change was an assumed decrease in risk of urinary tract infection (UTI) with single-use catheters. Given its economic/environmental impact (∼50-fold increase in cost and plastic waste) and a paucity
-
Unplanned Conversion from Partial to Radical Nephrectomy - An Analysis of Incidence, Etiology, and Risk Factors. J. Urol. (IF 7.6) Pub Date : 2022-06-24 Matvey Tsivian, Daniel D Joyce, Vignesh T Packiam, Christine M Lohse, Stephen A Boorjian, Theodora A Potretzke, George K Chow, Bradley C Leibovich, Vidit Sharma, R Houston Thompson
Conversions from partial (PN) to radical nephrectomy (RN) are uncommon and reports on this topic are rare. In this study we present a detailed analysis of conversions from PN to RN in a single institutional contemporary experience and provide an analysis of preoperative risk factors.
-
Does Smoking Cessation Reduce Bladder Cancer Recurrence? Letter. J. Urol. (IF 7.6) Pub Date : 2022-09-01 Richard A Watson
-
It Is Time to Liberalize the Administration of Botulinum Toxin in the Pediatric Urology Clinic! J. Urol. (IF 7.6) Pub Date : 2022-06-20 Armando J Lorenzo
-
Are We There Yet? Doctor of Osteopathic Medicine Students and the Urology Match. J. Urol. (IF 7.6) Pub Date : 2022-06-27 Mallory E McCormick,Casey A Seideman
-
Comparing Pediatric Ureteroscopy Outcomes with SuperPulsed Thulium Fiber Laser and Low-Power Holmium:YAG Laser. J. Urol. (IF 7.6) Pub Date : 2022-06-15 Christopher Jaeger, Caleb Nelson, Bartley Cilento, Tanya Logvinenko, Michael Kurtz
The thulium fiber laser is a promising new lithoptripsy technology never before studied in the pediatric population. Our center adopted the first platform in North America, the SuperPulsed thulium fiber laser (SPTF). We aimed to compare outcomes in pediatric ureteroscopy using the SPTF to those using the gold standard, low-power holmium:yttrium-aluminum-garnet (Ho:YAG) laser.
-
Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma. J. Urol. (IF 7.6) Pub Date : 2022-06-10 Lucas M Nogueira, Wesley Yip, Melissa J Assel, Andrew T Tracey, Nathan C Wong, Ricardo G Alvim, Hikmat Al-Ahmadie, Dean F Bajorin, Jonathan A Coleman
Little is known regarding the prognostic implications of variant histology in upper tract urothelial carcinoma (UTUC). We sought to evaluate the impact of variant histology UTUC on patient survival outcomes at our institution.
-
Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested-Case Control Study Using the French National Medical-Administrative Database. J. Urol. (IF 7.6) Pub Date : 2022-06-10 Marie France Malcher, Stephane Droupy, Claudine Berr, Abdelkrim Ziad, Helena Huguet, Jean-Luc Faillie, Chris Serrand, Thibault Mura
To analyze the relationship between use of anticholinergic drugs to treat overactive bladder (OAB) and risk of incident dementia in older patients; overall and for each drug separately.
-
Active Surveillance Versus Immediate Intervention for Small Renal Masses: A Cost-Effectiveness and Clinical Decision Analysis. J. Urol. (IF 7.6) Pub Date : 2022-06-10 Zhuo T Su, Hiten D Patel, Mitchell M Huang, Ridwan Alam, Joseph G Cheaib, Christian P Pavlovich, Mohamad E Allaf, Phillip M Pierorazio
Active surveillance (AS) with the possibility of delayed intervention (DI) is emerging as a safe alternative to immediate intervention for many patients with small renal masses (SRMs). However, limited comparative data exist to inform the most appropriate management strategy for SRMs.
-
Risk of Post-operative Thromboembolism in Men Undergoing Urologic Prosthetic Surgery: An Assessment of 21,413 Men. J. Urol. (IF 7.6) Pub Date : 2022-06-10 Kevin J Hebert, Rano Matta, Joshua J Horns, Niraj Paudel, Rupam Das, Tobias S Kohler, Alexander W Pastuszak, Benjamin J McCormick, James M Hotaling, Jeremy B Myers
To assess venous thromboembolism (VTE) and associated risk factors following artificial urinary sphincter (AUS) and inflatable penile prosthesis (IPP) surgery.
-
A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System (CKCis). J. Urol. (IF 7.6) Pub Date : 2022-06-10 Braden Millan, Rodney H Breau, Bimal Bhindi, Ranjeeta Mallick, Simon Tanguay, Antonio Finelli, Luke T Lavallée, Frédéric Pouliot, Ricardo Rendon, Alan I So, Lucas Dean, Jean-Baptiste Lattouf, Naveen S Basappa, Anil Kapoor
Percutaneous ablation therapy (AT) and partial nephrectomy (PN) are successful management strategies for T1a renal cancer. Our objective was to compare AT to PN with respect to recurrence-free survival (RFS) and overall survival (OS).
-
Acute Lower Back Pain after Intralesional Injection of Collagenase Clostridium histolyticum for Peyronie's Disease. J. Urol. (IF 7.6) Pub Date : 2022-06-09 John T Sigalos, Michelle K Li, Dar A Yoffe, Neilufar Modiri, Ming-Yeah Hu, Dyvon T Walker, Thomas W Gaither, Alvaro Santamaria, Keith V Regets, Sriram V Eleswarapu, Jesse N Mills
The safety label for collagenase Clostridium histolyticum was updated to include post-injection acute lower back pain as an adverse event observed with intralesional therapy for Peyronie's disease. Incidence and causality are unknown. We assessed frequencies and temporal associations for this adverse event in a large cohort.
-
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Non-seminomatous Germ-Cell Tumor. J. Urol. (IF 7.6) Pub Date : 2022-06-08 Jennifer M King, Sandra Althouse, Clint Cary, Timothy Masterson, Richard S Foster, Ryan Ashkar, Nasser H Hanna, Lawrence H Einhorn, Nabil Adra
The optimal management of patients with metastatic germ cell tumors (GCTs) who achieve a complete response (CR) after first-line chemotherapy remains unsettled. This study reports long-term outcomes of patients with GCT managed with surveillance after achieving a CR to first-line chemotherapy.
-
The Future of Urology: Results of the AUA Residents and Fellows Committee Essay Contest. J. Urol. (IF 7.6) Pub Date : 2022-06-06 Daniel A Igel,Avi Baskin
-
The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply. J. Urol. (IF 7.6) Pub Date : 2022-06-03 Mahmoud Abou Zeinab,Jihad Kaouk
-
The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Letter. J. Urol. (IF 7.6) Pub Date : 2022-06-03 Ye Tian,Heng Zhang,Guangheng Luo
-
Efficacy of Intramuscular Ketorolac for Preventing Renal Colic Post-stent Removal: Randomized Control Trial. J. Urol. (IF 7.6) Pub Date : 2022-06-02 Brett A Johnson, Igor Sorokin, Jodi Antonelli, Margaret Pearle
The treatment of stones ureteroscopically is associated with post-operative pain, thought to be due largely to the use of ureteral stents. In some, stent removal precipitates renal colic that can last from minutes to hours. We sought to determine if intramuscular ketorolac could reduce post-stent removal renal colic.
-
Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Non-Muscle-Invasive Bladder Cancer. J. Urol. (IF 7.6) Pub Date : 2022-05-31 Angela M Stover, Ramsankar Basak, Dana Mueller, Robert Lipman, Randall Teal, Alison Hilton, Kara Giannone, Myra Waheed, Angela B Smith
The trial "OPTimized Instillation of Mitomycin for Bladder Cancer Treatment" (Optima II, clinicaltrials.gov: NCT03558503) was a Phase 2b trial evaluating a nonsurgical alternative as a primary treatment for non-muscle-invasive bladder cancer (NMIBC). Patients received six weekly instillations of UGN-102, a mitomycin-containing reverse thermal gel. This is the first study to report on patientreported
-
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer. J. Urol. (IF 7.6) Pub Date : 2022-05-16 Max Kates, Ahmed M Mansour, Donald L Lamm, Neal Shore, Holly Maulhardt, Alison Wendt, James Verco, Alyson Marin, Karan Dewnani, Shelagh Verco, Gere S diZerega
We investigated the safety, preliminary efficacy, and immune effects of large surface area microparticle docetaxel (LSAM-DTX) administered by direct-injection after transurethral resection of bladder tumor (TURBT) and by intravesical instillation in high-risk non-muscle invasive bladder cancer (NMIBC).
-
Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin. J. Urol. (IF 7.6) Pub Date : 2022-05-13 Joshua J Meeks,Wade J Sexton,Peter E Clark
-
A randomized, single-blind clinical trial comparing robotic-assisted fluoroscopic-guided with ultrasound-guided renal access for percutaneous nephrolithotomy. J. Urol. (IF 7.6) Pub Date : 2022-05-13 Kazumi Taguchi, Shuzo Hamamoto, Atsushi Okada, Teruaki Sugino, Rei Unno, Taiki Kato, Hidekatsu Fukuta, Ryosuke Ando, Noriyasu Kawai, Yung Khan Tan, Takahiro Yasui
We conducted a randomized, single-blind clinical trial comparing the surgical outcomes of robotic-assisted fluoroscopic-guided (RAF group) and ultrasound-guided (US group) renal access in mini-percutaneous nephrolithotomy (PCNL).
-
Pro: Magnetic Resonance Imaging Targeting Leads to Overtreatment of Prostate Cancer. J. Urol. (IF 7.6) Pub Date : 2022-05-12 Andrew J Stephenson,Srinivas Vourganti
-
Con: Magnetic Resonance Imaging Targeting Leads to Overtreatment of Prostate Cancer. J. Urol. (IF 7.6) Pub Date : 2022-05-12 Mohummad Minhaj Siddiqui
-
DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial. J. Urol. (IF 7.6) Pub Date : 2022-05-12 Angelo Territo, Andrea Gallioli, Pietro Diana, Romain Boissier, Matteo Fontana, Josep Maria Gaya, Francesco Sanguedolce, Julio Calderón, Alberto Piana, Sofia Fontanet, Ferran Algaba, Joan Palou, Alberto Breda
The correct risk categorization and staging of upper tract urothelial cancer (UTUC) is key for disease management. Computed tomography urography (CTU) and urinary cytology have limited accuracy for risk stratification of UTUC. Ureteroscopy may increase the risk of bladder recurrence. Recently, Bladder EpiCheckTM (EpiCheck) showed a high accuracy in the detection of bladder cancer. The aim of the study
-
-
Robotic Urologic Oncologic Surgery: Ever-Widening Horizons. J. Urol. (IF 7.6) Pub Date : 2022-05-10 Giovanni Cacciamani,Mihir Desai,D Robert Siemens,Inderbir S Gill
-
In the Genetic Era Family History Is Just Not Enough!!! J. Urol. (IF 7.6) Pub Date : 2022-05-10 Yaara Ber,David Margel
-
Patient Engagement in Urological Research: A Call to Action. J. Urol. (IF 7.6) Pub Date : 2022-05-10 Mark Tyson,D Robert Siemens
-
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J. Urol. (IF 7.6) Pub Date : 2022-05-10 James A Eastham, Gregory B Auffenberg, Daniel A Barocas, Roger Chou, Tony Crispino, John W Davis, Scott Eggener, Eric M Horwitz, Christopher J Kane, Erin Kirkby, Daniel W Lin, Sean M McBride, Alicia K Morgans, Phillip M Pierorazio, George Rodrigues, William W Wong, Stephen A Boorjian
The summary presented herein represents Part III of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of radiation and offering several future directions of further relevant study in patients diagnosed with clinically localized prostate cancer. Please refer to Parts I and II for discussion of risk assessment, staging, and risk-based